News & Videos - BIOVENTIX ORD 5P - English

Bioventix Plc - Holding(s) in Company PR Newswire London, December 29 TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00B4QVDF07 Issuer Name BIOVENTIX PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Liontrust Investment Partners LLP City of registered office (if applicable) Country of registered office (if applicable) GB 4. Details of the shareholder...

Bioventix Plc - Result of AGM PR Newswire London, December 8 Bioventix plc (“Bioventix” or the “Company”) Result of AGM Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting held earlier today, all resolutions put to shareholders were duly passed. For further information please contact: Bioventix plc Peter Harrison Bruce Hiscock Chief Executive Officer Chief Financial Officer Tel: 01252 728 001 finnCap Ltd Geoff Nash/Simon Hicks Alice Lane Corporate Finance ECM Tel: 020...

Bioventix Plc - Director Dealing PR Newswire London, November 22 Bioventix plc (“Bioventix” or “the Company”) Director Dealing Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 22 November 2022 that on 21 November 2022 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 50 ordinary shares of 5 pence each...

Bioventix Plc - Posting of Annual Report and Notice of AGM PR Newswire London, November 8 8 November 2022 Bioventix plc ("Bioventix” or the "Company") Posting of Annual Report and Notice of AGM Bioventix plc (AIM: BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it has today posted its Annual Report for the year ended 30 June 2022 together with a Notice of Annual General...

Bioventix Plc - Director Dealing PR Newswire London, October 26 Bioventix plc (“Bioventix” or “the Company”) Director Dealing Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it has been notified that Bruce Hiscock , Chief Financial Officer of the Company, completed the following dealings in the Company’s ordinary shares of 5 pence in the Company...

Bioventix Plc - Results for the year ended 30 June 2022 PR Newswire London, October 24 Bioventix plc (“Bioventix” or “the Company”) Results for the year ended 30 June 2022 Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its audited results for the year ended 30 June 2022 . Highlights: · Revenue up 7% to £11.72 million (2021: £10.93 million) · Profit...

Bioventix Plc - Trading Update & Notice of Results PR Newswire London, September 13 Bioventix plc (“Bioventix” or “the Company”) Trading Update & Notice of Results Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, is pleased to announce a trading update for the year ended 30 June 2022 (“FY2022”). As announced in our interim results to 31 December 2021 , we had a...

Bioventix Plc - Holding(s) in Company PR Newswire London, August 25 TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00B4QVDF07 Issuer Name BIOVENTIX PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Danske Bank A/S City of registered office (if applicable) Copenhagen Country of registered office (if applicable) Denmark 4. Details of the shareholder Name...

Bioventix Plc - Holding(s) in Company PR Newswire London, July 27 TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00B4QVDF07 Issuer Name BIOVENTIX PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Danske Bank A/S City of registered office (if applicable) Copenhagen Country of registered office (if applicable) Denmark 4. Details of the shareholder Name...

Bioventix Plc - Director Dealing PR Newswire London, April 26 Bioventix plc (“Bioventix” or “the Company”) Director Dealing Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 26 April 2022 that on 25 April 2022 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 3 ordinary shares of 5 pence each in the...

Bioventix Plc - Interim Dividend Confirmation PR Newswire London, March 28 Bioventix plc (“Bioventix” or the “Company”) Interim dividend confirmation Bioventix plc (BVXP) (“Bioventix” or “the Company”), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Board has confirmed a cash interim dividend of 52p per ordinary share, which will be paid on 22 April 2022 . The...

Bioventix Plc - Half-year Report PR Newswire London, March 27 Bioventix plc (“Bioventix” or the “Company”) Unaudited Interim Results for the six months ended 31 December 2021 Bioventix plc (BVXP) (“Bioventix” or “the Company”), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its unaudited interim results for the six-month period ended 31 December 2021 . Highlights ·...

Bioventix Plc - Result of AGM PR Newswire London, December 9 Bioventix plc (“Bioventix” or the “Company”) Result of AGM Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting (“AGM”), all resolutions put to shareholders were duly passed. For further information please contact: Bioventix plc Peter Harrison Bruce Hiscock Chief Executive Officer Chief Financial Officer Tel: 01252 728 001 finnCap Ltd Geoff Nash/Simon Hicks Alice Lane Corporate Finance ECM Tel: 020 7220...

Bioventix Plc - Director/PDMR Shareholding PR Newswire London, November 22 Bioventix plc (“Bioventix” or “the Company”) Director Dealing Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 19 November 2021 that on 15 th November 2021 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 5 ordinary shares of...

Bioventix Plc - Posting of Annual Report and Notice of AGM PR Newswire London, November 11 Bioventix plc (“Bioventix” or the “Company”) Posting of Annual Report and Notice of AGM Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, confirms that its Annual Report and Accounts for the year ended 30 June 2021 and the Notice of Annual General Meeting (“AGM”) has been...

Bioventix Plc - Holding(s) in Company PR Newswire London, October 25 TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00B4QVDF07 Issuer Name BIOVENTIX PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Liontrust Investment Partners LLP City of registered office (if applicable) Country of registered office (if applicable) GB 4. Details of the shareholder...

Bioventix Plc - Director/PDMR Shareholding PR Newswire London, October 18 Bioventix plc (“Bioventix” or “the Company”) Director Dealing Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 18 October 2021 that on the same day, Bruce Hiscock , Chief Financial Officer of the Company, purchased a total of 416 ordinary shares of 5...

Bioventix Plc - Results for the year ended 30 June 2021 PR Newswire London, October 15 Bioventix plc (“Bioventix” or “the Company”) Results for the year ended 30 June 2021 Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its audited results for the year ended 30 June 2021 . Highlights: Revenue up 6% to £10.93 million (2020: £10.31 million) Profit before tax...

Bioventix Plc - Holding(s) in Company PR Newswire London, August 31 TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00B4QVDF07 Issuer Name BIOVENTIX PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Danske Bank A/S City of registered office (if applicable) Copenhagen Country of registered office (if applicable) Denmark 4. Details of the shareholder Name...

Bioventix Plc - Holding(s) in Company PR Newswire London, August 11 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : BIOVENTIX PLC 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) Non-UK issuer 2. Reason for the...